chemXplore tracks 97 projects in China, of which 48 are active.
Of the active ones, 32 new construction, 13 expansion and 3 revamp / retrofit.
26 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
The shipment marks a production-and-sales loop for products made by processing pyrolysis oil in existing refining and chemical units.
Plans include 56 new wells, full storage at 13 gas-storage sites and geothermal heating capacity of 146 million m².
Charging, battery swapping, hydrogen, energy storage and digital power trading are reshaping station operations.
The system calibrates four gauges in 5–6 minutes and achieves up to 99.7% reading recognition.
The event convened more than 200 guests and included agreements worth over $18.8 billion across oil and gas, equipment and low-carbon development.
Oral once-daily 50 mg FXIa inhibitor, given with antiplatelet therapy, cut ischemic stroke risk by 26% versus antiplatelets alone in a 12,327‑patient Phase III trial with similar major bleeding rates.
Agreement to cooperate on procurement and supply chain management, including supplier information exchange, best-practice sharing, and exploring integration of products, equipment and services.
PrevenTRON Phase III enrollment has started; Phase II TARBELA-AD launched for oral NLRP3 inhibitor RG6434; Brainshuttle trontinemab shows rapid amyloid removal; new Elecsys pTau217/pTau181 data published.
Quarterly revenue and profits rose; full-year forecasts upgraded; new 50,000 t/yr SAP plant set for July 2027; shareholder returns include a ¥6bn buyback and higher dividend.
Phase 3 ALKIVIA met primary and key secondary endpoints in combined IMNM and DM; argenx will file an sBLA for IMNM by end‑2026 following Breakthrough Therapy designation.